FDA Approves STRATTERA — Eli Lilly and Company

Eli Lilly and Company has announced that the capsule form of its branded attention deficit hyperactivity disorder (ADHD) medication STRATTERA (atomoxetine hydrochloride), has been granted approval by the FDA for new dosage strengths, expanding its availability for patients. This regulatory update bolsters the product’s market position against generics while enhancing its potential revenue share in the competitive ADHD treatment landscape.